Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics, Inc. (ANIK)
:ANIK
Total Valuation
Anika Therapeutics has a market cap or net worth of $142.48M. The enterprise value is $102.06M.
Market Cap$142.48M
Enterprise Value$102.06M
Share Statistics
Anika Therapeutics has 14,421,219 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14,421,219
Owned by Insiders4.25%
Owned by Institutions28.79%
Financial Efficiency
Anika Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -8.98%.
Return on Equity (ROE)-0.37
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-8.98%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee416.34K
Profits Per Employee-195.78K
Employee Count288
Asset Turnover0.59
Inventory Turnover1.84
Valuation Ratios
The current PE Ratio of Anika Therapeutics is ―. Anika Therapeutics’s PEG ratio is 0.13.
PE Ratio―
PS Ratio2.02
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-103.95
Price to Operating Cash Flow17.07
PEG Ratio0.13
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 119.91M and earned -56.38M in profits. Earnings per share was -3.83.
Revenue119.91M
Gross Profit76.00M
Operating Income-5.10M
Pretax Income-2.76M
Net Income-56.38M
EBITDA3.02M
Earnings Per Share (EPS)-3.83
Cash Flow
In the last 12 months, operating cash flow was 8.13M and capital expenditures -7.49M, giving a free cash flow of 648.00K billion.
Operating Cash Flow8.13M
Free Cash Flow648.00K
Free Cash Flow per Share0.04
Dividends & Yields
Anika Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change-44.30%
50-Day Moving Average9.46
200-Day Moving Average11.76
Relative Strength Index (RSI)54.30
Average Volume (3m)135.73K
Important Dates
Anika Therapeutics upcoming earnings date is Mar 10, 2026, After Close (Confirmed).
Last Earnings DateNov 5, 2025
Next Earnings DateMar 10, 2026
Ex-Dividend Date―
Financial Position
Anika Therapeutics as a current ratio of 4.88, with Debt / Equity ratio of 15.52%
Current Ratio4.88
Quick Ratio3.85
Debt to Market Cap0.00
Net Debt to EBITDA-9.83
Interest Coverage Ratio-2.18
Taxes
In the past 12 months, Anika Therapeutics has paid 6.06M in taxes.
Income Tax6.06M
Effective Tax Rate-2.19
Enterprise Valuation
Anika Therapeutics EV to EBITDA ratio is 70.40, with an EV/FCF ratio of -91.21.
EV to Sales1.77
EV to EBITDA70.40
EV to Free Cash Flow-91.21
EV to Operating Cash Flow39.35
Balance Sheet
Anika Therapeutics has $57.99M in cash and marketable securities with $24.51M in debt, giving a net cash position of $33.48M billion.
Cash & Marketable Securities$57.99M
Total Debt$24.51M
Net Cash$33.48M
Net Cash Per Share$2.32
Tangible Book Value Per Share$9.81
Margins
Gross margin is 59.57%, with operating margin of -4.25%, and net profit margin of -47.02%.
Gross Margin59.57%
Operating Margin-4.25%
Pretax Margin-2.31%
Net Profit Margin-47.02%
EBITDA Margin2.52%
EBIT Margin-4.25%
Analyst Forecast
The average price target for Anika Therapeutics is $16.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.00
Price Target Upside64.10% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-31.29%
EPS Growth Forecast65.68%